Board of Directors

Strong committed leadership focused on advancing the future of pain management

Kalman Kaufman

Chairman of the Board

Mr. Kaufman served as Corporate Vice President of Applied Materials Previously Mr. Kaufman was the founder and President of KLA Instruments Israel, and General Manager of Kulicke and Soffa Israel. Currently, he serves as chairman and director of several high-tech companies. Mr. Kaufman holds engineering degrees from the Technion – Israel Institute of Technology.

Dr. Douglas M Hansell

Board Member

Douglas M. Hansell, MD, MPH is the Vice President, Head of Medical Affairs, Medication Delivery, Acute Therapies & Clinical Nutrition at Baxter International Inc.

Dr Hansell has experience in large company MedDevice, healthcare startups, biotech & venture capital. Prior to Baxter, Dr. Hansell led the medical strategy that helped Cheetah Medical grow from startup to acquisition by Baxter in 4 years. Prior to Cheetah, Dr. Hansell was Chief Medical Officer for GE Healthcare and Covidien (Medtronic). Prior to industry, Dr. Hansell was CMO of an IDN in Boston. Alongside industry, he has a 30+ year academic career at Massachusetts General Hospital and Harvard Medical School in Boston.

Dr. Alan Levy

Board Member

Dr. Levy brings to Medasense over forty years of experience in the medical device industry. He spent twenty years at Johnson & Johnson developing many successful medical products and served in numerous leadership roles....

He then established and led multiple medical device companies, including Heartstream, that developed the first small, lightweight and easy-to-use automated external defibrillator.

Dr. Levy has also served as a Senior Advisor at Frazier Healthcare Ventures. He currently serves on the boards of multiple private and public healthcare companies.

Dr. Levy holds a BSc in Chemistry from City College of New York and a PhD and Honorary DSc from Purdue University.

Josep Ll. Sanfeliu

Board MembeR

Josep Ll. Sanfeliu is Managing Partner, President and Co-Founder at the venture capital firm ASABYS Partners (Barcelona). Formerly, he co-founded Ysios Capital where he was the partner in charge of health technology investments, investing in a total of 9 companies in the areas of medtech and digital health in Europe and in the U.S.

Previously Josep has worked in the pharmaceutical industry as Corporate Development Director at Almirall where he was involved with business development and in charge of M&A and corporate investments and also worked as General Manager leading operations in the segment of home-healthcare services at DomusVi.

Alejandro Weinstein

Board Member

Alejandro Weinstein is the co-founder and Partner at OTV ventures and WM Partners, and has more than 36 years of experience in the pharmaceutical industry. Prior to founding OTV and WM Partners, Mr. Weinstein was the CEO of CFR Pharmaceuticals S.A. (“CFR”), where he was responsible for a series of acquisitions transforming CFR from a local Chilean pharmaceutical company into a major global pharmaceutical company with presence in 26 countries across three continents. Under Mr. Weinstein’s leadership CFR completed an initial public offering and in September 2014, the Company was sold to Abbott Laboratories for approximately $2.9 billion.

In addition to his role as Board Member at Medasense Biometrics Ltd., Mr. Weinstein holds director or investor roles in various ventures in the pharmaceutical and healthcare industries, including Olive Tree Ventures, Vanterra and Davidson & W. He is a board member of Health Hero, Atida, Medneo GmbH, Grupo Procaps and Gauzy Ltd.

Mr. Weinstein received a Business and Administration degree from the Universidad Catolica de Chile and is a certified public auditor and accountant. He also a graduate of the OPM program at Harvard Business School.

Henry Weinstein

Board Member

Mr. Weinstein has more than eight years' experience as executive and investor in the life sciences industry. He most recently served as Vice President of Innovation and Development at Abbott Laboratories. Prior to that he was Vice President of Strategy and Innovation at CFR Pharmaceuticals....

He has a proven track record of launching over 300 products in the pharmaceutical industry in Latin America and completing more than 20 licensing deals including biotech products and medical devices. He currently serves as a Board Member of Convexity Scientific, Via Surgical and Dog Parker. He previously served on the board of BMRC, a biotech research consortium in Chile.

Galit Zuckerman Stark

Founder, CEO and board member

Ms. Zuckerman Stark brings to Medasense over fifteen years of entrepreneurship, management and engineering experience in both start-ups and large corporations. Ms. Zuckerman Stark founded Medasense upon discovering that while advanced algorithms are used frequently in many different industries such as semiconductors, communication, and many others, the discipline of medicine and specifically pain was still left behind....

Before founding Medasense she led a team of algorithm engineers at Applied Materials and worked at Nokia-Siemens and Nice Systems. She also served as a consultant for several start-up companies in the field of signal and image processing including BoneTone Communications which was successfully acquired by DSPG Inc in 2011.

Ms. Zuckerman Stark holds an MSc degree in Electrical Engineering (cum laude, Engineering Faculty Excellence Program) and a BSc in Computer Engineering (cum laude, Adi Lautman special program for outstanding students TAU) from Tel Aviv University, Israel.

Dr. Shmuel Cabilly

Board Observer

Dr. Cabilly is an investor and a board member of several companies. Dr. Cabilly developed a new technology for recombinant antibody production during a post-doctoral fellow at Genentech. This invention was patented in world patents known as “The Old Cabilly” and “The New Cabilly" patents....

Today there are already twenty drugs in the market based on this technology among which are Herceptin, Rituxan, Traceba, Raptiva, Xolair and more. Dr. Cabilly was also a co-founder and a chief scientist of Ethrog Biotechnology where he invented major technologies in the field of chemistry.

Robert Gavshon

Board Observer

Mr. Gavshon migrated to Australia from South Africa in 1978 where he was a partner in one of the largest law firms in that country. In Australia, initially he acted as Group General Counsel and Director of Corporate Affairs with worldwide responsibility for a multinational corporation based in Sydney....

Mr. Gavshon was a significant shareholder in, and served as an Executive Director of private and listed companies which developed icon brands. He has gained broad business experience in Australasia, USA and Asia and has been involved in a number of successful equity ventures where he has also taken Board and advisory roles.

Mr. Gavshon is widely respected for the extensive community service he has given and occupied leading positions in the Australian not-for-profit sector. He holds commerce and law degrees from the University of Witwatersrand, South Africa.